Upregulation of Epac-1 in Hepatic Stellate Cells by Prostaglandin E₂ in Liver Fibrosis Is Associated with Reduced Fibrogenesis

Marlies Schippers, Leonie Beljaars, Eduard Post, Sophie Lotersztajn, Catharina Reker-Smit, Bing Han, Pablo Munoz-Llancao, Martina Schmidt, and Klaas Poelstra

Groningen Research Institute for Pharmacy, Department of Pharmacokinetics, Toxicology and Targeting (M.S., L.B., E.P., C.R.-S., K.P.), and Groningen Research Institute for Pharmacy, Department of Molecular Pharmacology (B.H., P.M.-L., M.S.), University of Groningen, Groningen, The Netherlands; and INSERM U1149, Center for Research on Inflammation, Université Paris Diderot, Paris, France (S.L.)

Received April 28, 2017; accepted August 28, 2017

ABSTRACT

Exchange protein activated by cAMP (Epac-1) is an important signaling mechanism for cAMP-mediated effects, yet factors that change Epac-1 levels are unknown. Such factors are relevant because it has been postulated that Epac-1 directly affects fibrogenesis. Prostaglandin E₂ (PGE₂) is a well-known cAMP activator, and we therefore studied the effects of this cyclo-oxygenase product on Epac-1 expression and on fibrogenesis within the liver. Liver fibrosis was induced by 8 weeks carbon tetrachloride (CCL₄) administration to mice. In the last 2 weeks, mice received vehicle, PGE₂, the cyclo-oxygenase-2 inhibitor niflumic acid (NFA), or PGE₂ coupled to cell-specific carriers to hepatocytes, Kupffer cells, or HSC identified the latter cell as the key player in the observed effects on Epac-1 and Rho kinase. No significant alterations in protein kinase A expressions were found. In primary isolated HSC, PGE₂ elicited Rap1 translocation reflecting Epac-1 activation, and Epac-1 agonists attenuated platelet-derived growth factor–induced proliferation and migration of these cells. These studies demonstrate that PGE₂ enhances Epac-1 activity in HSC, which is associated with significant changes in (myo)fibroblast activities in vitro and in vivo. Therefore, Epac-1 is a potential target for antifibrotic drugs.

Introduction

Liver fibrosis is caused by an imbalanced remodeling process due to chronic inflammation associated with excessive scar tissue formation (Seki and Schwabe, 2015). Hepatic stellate cells (HSC), key players in this process, transform quiescent cells into proliferative, fibrogenic, and contractile myofibroblast-like cells in response to growth factors such as transforming growth factor (TGF)β and platelet-derived growth factor (PDGF)-BB (Seki and Schwabe, 2015). The differentiation and activation of HSC are tightly controlled by the activity of cAMP (Mallat et al., 1998). Increased intracellular cAMP levels inhibit fibroblast migration and proliferation and block the phenotype switch into myofibroblasts, leading to less scar tissue formation (Swaney et al., 2005).

Protein kinase A (PKA) is a well-known second-messenger system that mediates the effects of cAMP. More recently, exchange protein activated by cAMP (Epac) was identified as an important signaling mechanism for cAMP-mediated effects (Insel et al., 2012; Schmidt et al., 2013; Lezoualc’h et al., 2016). Epac is involved in the regulation of key cellular processes, such as calcium handling, neural signaling, inflammation, proliferation, and migration by promoting the exchange of GDP for GTP in the GTPase cycle (Schmidt et al., 2013; Yang et al., 2016; Yu et al., 2016). Two isoforms of Epac have been identified: Epac-1, found in heart, vasculature, brain, kidney, and lungs, and Epac-2, mostly found in brains and adrenal glands. Of interest, Epac-1 is reported to be involved in fibrogenesis. In several reports, significant lower Epac-1 expressions were observed during activation of myofibroblasts (Yokoyama et al., 2008; Insel et al., 2012; Schmidt et al., 2013).
However, to date, nothing is known about mechanisms or factors that can enhance Epac-1 expression and the consequences of this enhancement for fibrogenic processes in vivo (Insel et al., 2012).

The cyclo-oxygenase (COX) product prostaglandin E₂ (PGE₂) affects cAMP levels directly in most cell types. In fibroblasts, PGE₂ exerts antifibrotic activities through cAMP activation by binding to EP2 or EP4 receptors (Rutter et al., 1989; Mallat et al., 1998; Weinberg et al., 2009). We therefore investigated the effects of PGE₂ and the COX-inhibitor nimicum acid (NFA) on Epac-1 expression levels in the carbon tetrachloride (CCL₄)-induced mouse model for liver fibrosis. In addition, we used a cell-specific delivery approach to deliver PGE₂ to several resident hepatic cells to identify its most important target cell in vivo. Our studies show a decreased Epac-1 protein expression in fibrotic livers relative to normal livers. These Epac-1 levels were restored by PGE₂ delivery to HSC, but not by its delivery to hepatocytes or Kupffer cells. In HSC this was associated with reduced fibrogenic activity both in vitro and in vivo. Our studies indicate a significant role for Epac-1 during liver fibrosis and delineate a pathway to enhance these Epac-1 levels.

Materials and Methods

Synthesis of Drug Carriers and PGE₂ Constructs

PDGFβ-receptor-recognizing peptides [peptide derived from PDGF B chain (pPB); prepared by Ansynth Service BV, Roosendaal, The Netherlands], mannose (p-aminophenyl-D-mannopyranosiose; Sigma-Aldrich, St. Louis, MO), and lactose (Merck, Darmstadt, Germany) were covalently coupled to human serum albumin (HSA) to yield, respectively, pPB coupled to HSA (PH), lactosylated HSA (LH), or mannosylated HSA (MH), as previously described (Beljaars et al., 1998, 2003).

PGE₂ (Cayman Chemicals, Ann Arbor, MI) was coupled to PH, LH, and MH, yielding PGE₂ coupled to pPB-HSA (PPH), PGE₂-lactosylated HSA (PLH), and PGE₂-mannosylated HSA (PMH). First, the carboxylic acid group of PGE₂ was activated by N,N-dicyclohexylcarbodiimide and N-hydroxysuccinimide solution. This PGE₂/N,N-dicyclohexylcarbodiimide/hydroxysuccinimide solution was reacted overnight at room temperature with PH, LH, or MH (molar ratio HSA/PGE₂ = 1:60). All products were subsequently dialyzed for at least 24 hours against phosphate-buffered saline (PBS) using a 10-kDa dialysis cassette (Slide-A-Lyzer 10K; Pierce Biotechnology, Rockford, IL) and further purified using chromatographic techniques. Conjugates were lyophilized and stored at −20°C. The amount of PGE₂ coupled to each carrier was assessed by mass spectrometry.

Cell Experiments

Primary rat HSC were isolated from livers of male Wistar rats (>400 g; Harlan, Zèist, The Netherlands), as described (Beljaars et al., 2003), and cultured on plastic for 10 days to obtain an activated cell type.

HepG2, RAW264.7, NIH/3T3 fibroblasts (all derived from American Type Culture Collection, Manassas, VA), and LX2 cells were used as model cells for, respectively, hepatocytes, macrophages, and HSC. Data are presented as the mean of three experiments, each performed in duplicate.

Concentrations used (unless otherwise stated) were 5 μM PGE₂, 50 μM Epac-1 agonist (8-pCPT-2′-O-Me-cAMP; Biolog, Bremen, Germany), 500 μM PKA agonist (N⁵,9-benzoyladenosine-3′,5′-cyclic monophosphate sodium salt; Biolog), 50 ng/ml PDGF-BB (PeproTech, Rocky Hill, NJ), and 5 ng/ml TGFβ (Roche Diagnostics, Mannheim, Germany).

Proliferation Assay. Primary rat HSC (2 × 10⁵ cells/well) were seeded in 12-well plates and grown for 2 days. After 24-hour starvation, PGE₂, Epac-1, or PKA agonist was added along with PDGF-BB. After 18 hours, ³H-thymidin (0.25 μCi/ml) was added for 6 hours. Cells were washed, fixed with 5% trichloracetic acid, and lysed with 1 M NaOH, and radioactivity was counted.

Migration Assay. Primary rat HSC (6 × 10⁵ cells/well) were cultured in Transwell chambers (8 μm pore size; Costar, New York, NY) with PGE₂ or agonists. PDGF-BB was added to the lower chamber. After 24 hours, membranes were fixed and stained with hematoxylin. Cells on both sides of the membrane were counted in at least five fields/membrane (magnification, 40×). Migration was calculated as percentage of cells in the lower chamber relative to total cell number.

In Vitro Effects of PGE Conjugates. HepG2 cells (150,000 cells/well) were incubated with PGE₂ and equimolar amounts of PLH for 60 minutes. Cells were processed and used for Western blot analysis using vasodilator-stimulated phosphoprotein-1 antibody. RAW264.7 cells were incubated with 100 ng/ml lipopolysaccharide plus 10 μM PGE₂, equimolar amounts of PMH, or vehicle. After 24 hours, medium was harvested and total nitric oxide production was assessed (Melgert et al., 2001). LX2 cells were grown to confluence in 12-well plates. A standard scratch was made, after which cells were incubated for 24 hours with 10 ng/ml PDGF-BB plus 5 μM PGE₂, equimolar amounts of PP, or vehicle. The scratch size was measured using imaging techniques at t = 0 and t = 24 hours, yielding the percentage wound healing.

Epac-1 and PKA Expression. The 3T3 fibroblasts (100,000 cells/well) were incubated with PGE₂ (0.1, 1, 5, and 10 μM) for 6, 24, and 48 hours. Cells were homogenized and processed for Western blot and polymerase chain reaction (PCR) analysis.

Rap1 Expression. The 3T3 cells (25,000 cells/well), seeded in glass labtak, were incubated with 10 μM PGE₂ and 20 μM Epac-1 antagonist 5,7-dihydro-6-fluoro-3,4-dihydro-2-methyl-1H-quinolone-4-carboxaldehyde (CE3F4) (Courilleau et al., 2012) for 60 minutes. After fixation in aceton/methanol (1:1), Rap1 was stained (overnight, 4°C) using the primary antibody (Santa Cruz Biotechnology, Heidelberg, Germany), and subsequently visualized using Alexa488 goat anti-rabbit IgG (ThermoFisher Scientific; Landsmeer, The Netherlands) and 4′,6-diamidino-2-phenylindole.

Animal Experiments

All animal experiments were approved by the Animal Ethics Committee of the University of Groningen (Groningen, The Netherlands).

CCL₄ Model. Male BALB/c mice (20–22 g; Harlan) received CCL₄ for 8 weeks, according to standard protocols (Beljaars et al., 2003). At weeks 7 and 8, mice also received i.v. (i.e., 3 times/week) 0.5 mg/kg PGE₂, 5 mg/kg NFA, vehicle (PBS), PH, PH, PMH, MH, PLH, or LH (n = 6–9/group). All animals received the same PGE₂ dose either free or bound to the albumin drug carrier. Mice were sacrificed at week 8. Two animals from each group received i.v. a PGE₂-loaded carrier 15 minutes prior to sacrifice to check whether the PGE₂-carrier conjugate still accumulated in the designated target cell. The liver enzymes alanine transaminase (ALT) and aspartate transaminase, reflecting liver damage, were measured in plasma according to routine methods at the clinical chemistry laboratory of the University Medical Center Groningen (Groningen, The Netherlands).

Human Tissue

Human liver tissue samples were obtained from the Department of Surgery and Liver Transplantation (University Medical Center Groningen). All patients signed an informed consent for the use of residual tissue for research purposes. Experimental protocols were approved by the Medical Ethical Committee, and anonymized tissue samples were used according to Dutch guidelines (http://www.federa.org/gedragscodes-codes-conduct-en). Normal human liver tissue was obtained from donor livers discarded for transplantation for technical reasons. Cirrhotic human liver tissue was obtained from patients undergoing liver transplantation, and indications for transplantation were primary sclerosing cholangitis, primary biliary cirrhosis, congenital cirrhosis, alcohol-induced liver disease, acute liver failure, and Wilson’s cirrhosis. All human liver material was anonymized, and available patient characteristics are listed in Table 1.
**Tissue Analysis**

**Immunohistochemistry.** Cells and cryostat sections were stained according to standard methods. Primary antibodies used in this study were as follows: mouse anti-α-smooth muscle actin (SMA) and anti-desmin from Sigma-Aldrich; goat anti-collagen I from Southern Biotechnology Associates (Birmingham, AL); antiphosphorylated myosin light chain (PMLC2/Ser19) from Cell Signaling Technology (Danvers, MA); rat anti-CD68 (AbD Serotec, Dusseldorf, Germany); rabbit anti-CYP2E1 (Millipore, Darmstadt, Germany); and goat anti-HSA (MPBiomedicals, Eschwege, Germany). Species-specific horseradish peroxidase and fluorescein isothiocyanate/tetramethylrhodamine isothiocyanate–conjugated secondary antibodies were from Dako (Glostrup, Denmark). Stainings were quantified by analyzing complete sections from three different liver lobes of each animal at magnification 10 × 10 using Cell D image-analyzing software (Olympus, Hamburg, Germany).

Western blot analysis was performed according to standard methods with 100 μg protein loaded on a 12% gel and using the primary antibodies, as follows: goat anti–phosphorylated SMAD (pSMAD) 2/3 and goat anti–Epac-1 (Santa Cruz Biotechnology); goat anti–PKA (Cα) (BD Transduction Laboratories, Vianen, The Netherlands); and mouse anti–α-SMA, goat anti-collagen I, and β-actin (Sigma-Aldrich). Signals were quantified with Genetools (Syngene, Cambridge, UK) using ECL reagent (Perkin-Elmer, Boston, MA). Of each animal, samples from three different liver lobes were analyzed and corrected for the housekeeping gene β-actin.

**Quantitative Real-Time PCR.** Total RNA was isolated by RNeasy mini kit (Qiagen, Hilden, Germany) and reverse transcribed using cDNA synthesis kit (Promega, Leiden, The Netherlands). Reverse transcription PCR was performed using SYBR Green PCR Master Mix (ThermoFisher Scientific) or SensiMix SYBR kit (Bioline, London, UK), according to standard methods, with β-actin as housekeeping gene. Primers (Sigma Genesys, Haverhill, UK) used were as follows: α-SMA (forward: 5'-ACTACTGCGCCGCTGAGAT-3', reverse: 5'-CCAATGGTTGAAGGTCTCAAA-3'), collagen Iα1 (forward: 5'-TGACTGGAAGACGCCGAGATG-3', reverse: 5'-ATCCATCAGGTCTGCTCTG-3'), Epac-1 (forward: 5'-CATGTCTGTCTGTGGCCGCGGA-3', reverse: 5'-GTTCTCTGAGGCTGGGCTC-3'), human Epac-1 (forward: 5'-CATG-TGAAACAGCGACTTGGGC-3', reverse: 5'-GAGGTCCAGCTCTTCATC-3'), PKA (catalytic subunit) (forward: 5'-GGTTGGTAGCGCC-CACGCC-3', reverse: 5'-GGGGGCCCTCAAGAGGTCCCA), and β-actin (forward: 5'-GGGATCTGCGCTGCTGCTGGA-3', reverse: 5'-GGGTTGGGGACGCTC-3').

**PGE2 Enzyme-Linked Immunosorbent Assay.** Liver samples were homogenized, and PGE2 amounts were assessed using the monoclonal PGE2 enzyme immunoassay kit (Cayman Chemicals), according to manufacturer’s instructions.

**Statistical Analysis**

Results are expressed as mean ± S.E.M. Statistical analyses were performed using the Mann–Whitney test and considered significant at P < 0.05.

<table>
<thead>
<tr>
<th>TABLE 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient characteristics of the human livers used in this study</td>
</tr>
<tr>
<td>Normal Livers</td>
</tr>
<tr>
<td>Age (min–max) years</td>
</tr>
<tr>
<td>Gender</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

F, female; M, male; max, maximum; min, minimum.

**Results**

**PGE2 and NFA Affect Liver Fibrosis in CCL4-Treated Mice.** Mice received CCL4 for 8 weeks to induce liver fibrosis. During the last 2 weeks of CCL4 administration, the mice were treated with PGE2 (n = 9), the COX-2 inhibitor NFA (n = 6), or vehicle (PBS; n = 9). Normal mice, receiving only PBS, served as control (n = 9). Plasma levels for ALT and aspartate transaminase indicated significant liver damage in all CCL4-treated mice (see Table 2). No major differences in damage were seen between fibrotic animals receiving different compounds in the final 2 weeks, although a reduced average in plasma ALT level was seen in NFA-treated animals (P < 0.05). Markers reflecting HSC activation (α-SMA) and matrix deposition (collagen I) were examined both at the mRNA (Supplemental Fig. 1) and protein level (Fig. 1). Immunohistochemistry and reverse transcription PCR analysis showed that PGE2-treated mice displayed significantly less intracellular α-SMA and collagen I expression levels compared with CCL4 mice receiving no treatment (Fig. 1, A–D). In contrast, NFA induced a significant increase in α-SMA and collagen I protein levels in fibrotic mice compared with CCL4 mice receiving no treatment. pSMAD2/3 expression levels, indicating TGFβ signaling, were strongly enhanced in CCL4-receiving mice treated with PBS (Fig. 1E). Treatment with PGE2 significantly reduced these levels, whereas NFA administration enhanced pSMAD2/3 levels in fibrotic animals.

Measurement of intraperitoneal PGE2 levels revealed that CCL4 mice displayed increased intraperitoneal PGE2 levels relative to healthy animals (P < 0.01, Fig. 1F). PGE2 treatment significantly reduced these levels compared with untreated fibrotic mice (P < 0.01). NFA treatment completely abolished intraperitoneal PGE2 production in fibrotic animals.

**PGE2 Enhances Epac-1 Expression and Attenuates Rho Activity In Vivo.** Previous in vitro studies showed that PGE2 activates cAMP in myofibroblasts (Huang et al., 2008). We now examined intraperitoneal expression levels of both cAMP mediators PKA and Epac-1 in CCL4-treated mice. In fibrotic livers, a significant reduction in Epac-1 protein expression levels was observed relative to healthy mice livers (Fig. 2A), in agreement with previous reports (Yokoyama et al., 2008; Insel et al., 2012; Schmidt et al., 2013). PGE2 treatment significantly restored Epac-1 levels in fibrotic livers. In contrast, NFA treatment further reduced Epac-1 levels in fibrotic animals. Western blot analysis did not reveal significant changes in PKA expression levels in CCL4-treated animals as compared with normal mice, and expression levels for PKA were also not affected by PGE2 or NFA treatment.

We also examined human livers for Epac-1 expression. Western blots revealed that Epac-1 expression levels were significantly reduced also in human fibrotic livers, irrespective of etiology, compared with control livers (Fig. 2C).

Rho kinase is known to be a downstream target of Epac-1 (Roscioni et al., 2011; Schmidt et al., 2013). Rho kinase in turn stimulates fibroblast-to-myofibroblast transdifferentiation, migration, and contraction of these cells via phosphorylation of the myosin light chain (i.e., formation of PMLC) (Mack et al., 2001). This PMLC stimulates myosin II ATPase activity and contraction of actin fibers in HSC, leading to portal hypertension, one of the hallmarks of fibrosis (Klein et al., 2012). Recently, reports showed that Epac-1 inhibits phosphorylation of myosin light chain. In fibrotic mice, clear
staining for PMLC in the fibrotic bands was visible, whereas little or no expression was seen in healthy animals (Fig. 2D).
PMLC staining colocalized with desmin staining, the marker for HSC. Fibrotic animals treated with PGE2 displayed no PMLC staining in fibrotic bands or in any desmin-positive cell at all.

TABLE 2
Plasma ALT and aspartate aminotransferase levels (avg. ± S.E.M.) in each experimental group at the time of sacrifice

<table>
<thead>
<tr>
<th></th>
<th>AST (U/L)</th>
<th>ALT (U/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthy</td>
<td>33 ± 9</td>
<td>13 ± 3</td>
</tr>
<tr>
<td>CCL4</td>
<td>572 ± 129 (**relative to healthy)</td>
<td>182 ± 37 (**relative to healthy)</td>
</tr>
<tr>
<td>CCL4 + PGE2</td>
<td>326 ± 117 (ns relative to CCL4)</td>
<td>152 ± 34 (ns relative to CCL4)</td>
</tr>
<tr>
<td>CCL4 + NFA</td>
<td>704 ± 118 (ns relative to CCL4)</td>
<td>62 ± 12 (*relative to CCL4)</td>
</tr>
</tbody>
</table>

AST, aminotransferase; ns, nonsignificant.
*P < 0.05; **P < 0.01; ***P < 0.001.
Collectively, our data show that PGE$_2$ attenuated $\alpha$-SMA and collagen I expression in fibrotic mice, which is associated with an increase in Epac-1 levels and inhibition of its downstream target Rho kinase compared with untreated fibrotic mice. In contrast, NFA increased HSC activation and collagen deposition and further reduced Epac-1 expression in fibrotic animals.

**Cell-Specific Delivery of PGE$_2$ to Resident Hepatic Cells.** Epac-1 proteins are expressed in many resident and circulating cells. We therefore used a drug-targeting approach to assess which cell type is involved in the observed effects on intrahepatic Epac-1 levels and fibrogenesis. We therefore coupled PGE$_2$ to cell-specific carriers directed at either HSC, Kupffer cells, or hepatocytes (Fig. 3A). Lactosylated human serum albumin (LH), which binds to the asialoglycoprotein receptor, is a well-known carrier to hepatocytes (Beljaars et al., 1998). PDGF$\beta$ receptors and mannose receptors are highly expressed on respectively activated HSC (Seki and Schwabe, 2015) and macrophages (Beljaars et al., 1998;...
Fig. 3. Cell-specific effects of PGE₂ targeted to HSC (PPH), to Kupffer cells (PMH), or to hepatocytes (PLH) on fibrogenic markers and on Epac-1 and PKA expressions in fibrotic livers in mice. (A) Schematically outlines the different constructs and target cells. (B) Pharmacological effects of PGE₂ coupled to pPB-HSA (PPH), to mannosylated HSA (PMH), or to lactosylated HSA (PLH) in cell cultures. A wound-healing assay in cultures of fibroblasts was used to test the activity of PPH. The biologic activity of PMH was assessed by lipopolysaccharide-induced nitric oxide production in RAW264.7 macrophages, and the phosphorylation of vasodilator-stimulated phosphoprotein in HEPG2 cells was used to assess the activity of PLH. (C) Double staining for the PGE₂ conjugate (with an antibody directed against HSA) and the cellular marker desmin (marker for HSC), CD68 (marker for KC), or CYP2E1 (hepatocyte marker). Arrowheads show double staining for desmin and PPH, double staining of CD68 and PMH, and double staining for CYP2E1 and PLH in livers of fibrotic mice, 30 minutes after injection of the compounds (original magnification, 20 × 10, inserts 40 × 10). (D) Protein
Melgert et al., 2001), which both are abundantly present in fibrotic livers. These receptors are suitable targets for respectively HSC and KC delivery. Therefore, we coupled PDGFβ receptor-recognition peptides to HSA (pPB-HSA) to obtain a HSC-selective carrier and attached mannose to HSA (MH) to reach macrophages. The cell specificity of all these carriers has been described in vivo in earlier reports (Beljaars et al., 1998, 2003; Melgert et al., 2001). PGE2 was subsequently coupled to each carrier. Cell specificity of carriers was retained after attachment of PGE2: PGE2 attached to pPB-HSA (−PPH) was found in Desmin-positive cells, reflecting HSC, 15 minutes after its administration to fibrotic mice. Mannosylated HSA (−PMH) was found in CD68-positive KC cells and lactosylated HSA (−PLH) contained with the hepatocyte marker (CYP2E1) (Fig. 3C). All three PGE2 conjugates, i.e., PPH, PMH, and PLH, also were pharmacologically active compounds as tested in cell cultures: PPH significantly attenuated PDGF-induced activities of fibroblasts in vitro, PMH significantly attenuated the lipopolysaccharide-induced nitrogen oxide species production of RAW264.7 macrophages, and PLH induced vasodilator-stimulated phosphoprotein phosphorylation in HEPG2 cells, all similar to free PGE2 (Fig. 3B).

Fibrotic mice treated for 2 weeks with the HSC-selective PGE2 conjugate PPH displayed a significant reduction in collagen I expression compared with untreated fibrotic mice (Fig. 3D). Mice receiving the carrier alone (i.e., PH) displayed no such reduction. Treatment of fibrotic mice with the KC-selective PMH conjugate or the carrier MH alone led to the opposite; upregulation of collagen I compared with the vehicle group was found. Treatment with the hepatocyte-selective PLH conjugate or the carrier alone (LH) did not induce significant alterations in collagen I deposition.

Subsequently, we studied Epac-1 and PKA expression levels in mice treated with PGE2 conjugates or their respective control compounds. Only in livers of PPH-treated mice did we find significant upregulation of Epac-1 expression compared with PBS-treated fibrotic mice (Fig. 3E). All other treatments did not induce any alteration in Epac-1 expression. PKA expression was not different from untreated fibrotic mice in any of the groups (Fig. 3E). The increase in Epac-1 expression in mice treated with the HSC-selective PGE2 conjugate was, similar to PGE2 alone (see also Fig. 2E), associated with a significant reduction in PMLC expression in HSC (desmin-positive cells) in fibrotic livers (Fig. 4). Other treatments (i.e., PLH and PMH) and controls did not induce a change in hepatic PMLC staining relative to untreated fibrotic mice (data not shown). This indicates that HSCs are the key players of PGE2-mediated effects on Epac-1 untreated fibrotic mice (Fig. 5). Epac-1 is known to induce translocation of Rap1 from the cytosol to plasma membranes (Yang et al., 2016). Figure 5 shows Rap1 staining evolving from a general weak cytoplasmatic staining within fibroblasts to a more concentrated intense staining along membranes after addition of PGE2, indicating relocalization and concentration of Rap1. In turn, the PGE2-induced relocalization was inhibited by the Epac-1 inhibitor CE3F4 (Courilleau et al., 2012). This indicates the involvement of Epac-1 in this PGE2-mediated effect.

Effects of Epac-1 and PKA Agonists in Primary HSC. Our in vivo data implicate that fibrogenic mediators reduce Epac-1 expression, whereas Epac-1 enhancement leads to inhibition of HSC activities. We tested this in vitro using primary HSC, isolated from rats. In these primary cells, PDGF-BB and TGFβ significantly reduced Epac-1 mRNA expression levels compared with unstimulated cells, whereas no changes in PKA mRNA levels were seen (Fig. 6A). Subsequently, the PKA agonist 9β-benzoyladenosine-3',5'-cyclic monophosphate sodium salt and the Epac-1 agonist 8-pCPT2'-O-Me-cAMP (Roscioni et al., 2009, 2011) were used to study the effects of the Epac-1 and PKA signaling pathway on PDGF-induced migration and proliferation in recombinant HSC (rHSC). Both agonists attenuated PDGF-induced migration of rat hepatic stellate cells (rHSC) (Fig. 6B). The Epac-1 agonist also inhibited PDGF-induced proliferation in rHSC, whereas the PKA agonist had no effect (Fig. 6B).

Discussion

This study demonstrates the involvement of the cAMP effector Epac-1 in the regulation of hepatic fibrogenesis in vitro and in vivo. Epac proteins, alone or in concert with PKA, are closely involved in the regulation of pivotal processes, including cell survival, proliferation and differentiation, immune responses, and signaling cascades (Yokoyama et al., 2008; Roscioni et al., 2011; Lezoualc’h et al., 2016). Despite these activities, little is known about Epac during liver fibrosis in vivo. The relevance of Epac-1 during fibrogenesis has been inferred from studies showing a reduced Epac-1 expression after fibroblast activation in several organs (Roscioni et al., 2011; Insel et al., 2012; Schmidt et al., 2013; Lezoualc’h et al., 2016). It was therefore suggested that upregulation of Epac-1 might attenuate fibrosis (Insel et al., 2012; Schmidt et al., 2013). However, methods to achieve such an upregulation were unknown (Insel et al., 2012). Our in vivo experiments in fibrotic mice now show that Epac-1 can be upregulated in HSC by PGE2. This is associated with reduced fibrogenesis in vivo.

PGE2 was found to exert significant antifibrotic effects in mice with liver fibrosis, as reflected in this study by reduced collagen I, α-SMA, and pSMA/2/3 levels. The COX-2 inhibitor NFA induced the opposite effects on these parameters. This profibrotic effect cannot be explained by increased damage induced by NFA (see Table 2). Also, others found a profibrotic effect of COX-2 inhibitors (Gilroy et al., 1999), but the mechanism behind this always has been unclear. Our studies suggest a role for Epac-1 in this cascade of cyclo-oxygenase–induced effects.

levels for collagen type I in livers of fibrotic mice treated with PPH (n = 9/group), PMH (n = 6/group), or PLH (n = 6/group) measured by Western blot analysis. (E) Hepatic protein levels for cAMP effectors Epac-1 and PKA in mice after treatment with the different PGE2 constructs. Vehicle (PBS) or drug carriers without PGE2 (i.e., PH, MH, or LH) served as controls. *P < 0.05, **P < 0.01, ***P < 0.001, #P < 0.05 as compared to control.
PGE₂ signals through intracellular cAMP inducing PKA or Epac-1 activation. Whereas PKA levels did not change in our studies, Epac-1 dropped significantly during hepatic fibrogenesis in mice and after HSC activation in vitro, confirming earlier reports (Insel et al., 2012). A limited survey in human tissue samples indicates that this reduction also occurs in patients with different liver diseases. PGE₂ and NFA displayed opposite effects in fibrotic livers: a strong upregulation of Epac-1 was seen after PGE₂ treatment, and a downregulation after NFA treatment. NFA treatment was shown to abolish intrahepatic PGE₂ production, confirming effective inhibition. These observations suggest that the antifibrotic effects of PGE₂ are, at least partly, mediated by Epac-1.

Our data seemingly reveal a contradiction. We showed that PGE₂ administration enhanced Epac-1 expression in fibrotic livers, yet liver fibrosis is associated with high hepatic PGE₂ levels (Fig. 1F) and reduced Epac-1 expression (Fig. 2C). Moreover, PGE₂ treatment attenuated intrahepatic PGE₂ production, yet enhanced Epac-1 levels. It is clear that total intrahepatic PGE₂ content does not correlate with Epac-1 or fibrosis. Of note, the plasma half-life of the administered PGE₂ (5 minutes) is too short to be detectable at the time of sacrifice (24 hours after injection). PGE₂ and NFA are both anti-inflammatory compounds and consequently can both attenuate PGE₂ production by inflammatory cells (Gilroy et al., 1999). At the same time, they have opposite effects on fibrogenesis, HSC activation, and Epac-1 levels (see Figs. 1 and 2A). Cell-specific delivery of PGE₂ to HSC did enhance intrahepatic Epac-1 levels and attenuated fibrogenesis and HSC activation. Therefore, it can be deduced that PGE₂ affects fibrosis via an effect on Epac-1 levels specifically within HSC, irrespective of the total PGE₂ content within livers.

One of the downstream targets of Epac-1 is Rho kinase (Yu et al., 2016), which was found to be downregulated by Epac-1 (Roscioni et al., 2011; Rajagopal et al., 2013; Schmidt et al., 2013). Rho kinase stimulates the transdifferentiation of HSC into collagen-producing myofibroblast-like cells via phosphorylation of its downstream substrate, myosin light chain (Mack et al., 2001). This prompted us to examine PMLC levels in fibrotic livers. Indeed, PMLC was abundantly expressed in desmin-positive cells in fibrotic septa in livers of untreated mice. In contrast, in fibrotic mice treated with PGE₂, PMLC

![Fig. 4. Effects of PGE₂ targeted to HSC (PPH), free PGE₂, or carrier (PH) on intrahepatic pMLC expression (reflecting Rho kinase activity) in fibrotic livers in vivo. Representative pictures of immunofluorescent staining for PMLC (=Rho kinase marker: green) and desmin (HSC marker: red). Strong staining for PMLC can be seen in desmin-positive septae, but this staining is absent in fibrotic animals treated with PPH and PGE₂.](image)

![Fig. 5. Effects of PGE₂ on intracellular localization of Rap1 in NIH/3T3 cells. Pictures show fluorescent staining for Rap1, which is a downstream effector of Epac-1. Note the more intense staining along the plasma membranes in PGE₂-treated cultures, which is reversed by addition of the Epac-1 inhibitor CE3F4 (original magnification, 40 × 10).](image)
formation was completely absent, indicating a lower Rho kinase activity at these sites. Rho kinase has profound effects on portal pressure via actin-filament contraction in HSC (Klein et al., 2012), and portal hypertension is a key factor in clinical complications during cirrhosis, so the modulation of Rho kinase activity by PGE2 in HSC is quite relevant.

PGE2 is pleiotropic molecule affecting many cell types, including (circulating) inflammatory cells, smooth muscle cells, hepatocytes, and macrophages (Hui et al., 2004; Haag et al., 2008). To investigate which cell type was responsible for the observed alterations, we used different albumin-based cell-selective carriers. Cell selectivity of the applied carriers has been extensively demonstrated in previous studies (Beljaars et al., 1998, 2003). Cell specificity was verified for all PGE2 constructs: all constructs were taken up by the designated target cells, as illustrated by double staining for albumin and specific cell markers. Also, pharmacological activity of constructs was verified in cell lines expressing the designated target receptor (i.e., the PDGFβ receptor, mannose receptor, or the asialoglycoprotein receptor), and we started therapies in a late stage of disease, when target receptor expression is high. In vivo, only HSC-selective PGE2 delivery inhibited the CCL4-induced scar tissue formation, normalized Epac-1 expression levels, and abolished PMLC protein expression, thereby excluding a role for KC, hepatocytes, and circulating or infiltrating inflammatory cells. We did not test the effect of PGE2 on sinusoidal endothelial cells yet. Studies with PGE2 coupled to endothelial-specific carriers need to be performed to exclude a role for KC, hepatocytes, and circulating or infiltrating inflammatory cells. We did not test the effect of PGE2 on sinusoidal endothelial cells yet. Studies with PGE2 coupled to endothelial-specific carriers need to be performed to exclude a role for KC, hepatocytes, and circulating or infiltrating inflammatory cells. We did not test the effect of PGE2 on sinusoidal endothelial cells yet. Studies with PGE2 coupled to endothelial-specific carriers need to be performed to exclude a role for KC, hepatocytes, and circulating or infiltrating inflammatory cells. We did not test the effect of PGE2 on sinusoidal endothelial cells yet. Studies with PGE2 coupled to endothelial-specific carriers need to be performed to exclude a role for KC, hepatocytes, and circulating or infiltrating inflammatory cells. We did not test the effect of PGE2 on sinusoidal endothelial cells yet. Studies with PGE2 coupled to endothelial-specific carriers need to be performed to exclude a role for KC, hepatocytes, and circulating or infiltrating inflammatory cells. We did not test the effect of PGE2 on sinusoidal endothelial cells yet. Studies with PGE2 coupled to endothelial-specific carriers need to be performed to exclude a role for KC, hepatocytes, and circulating or infiltrating inflammatory cells. We did not test the effect of PGE2 on sinusoidal endothelial cells yet. Studies with PGE2 coupled to endothelial-specific carriers need to be performed to exclude a role for KC, hepatocytes, and circulating or infiltrating inflammatory cells. We did not test the effect of PGE2 on sinusoidal endothelial cells yet. Studies with PGE2 coupled to endothelial-specific carriers need to be performed to exclude a role for KC, hepatocytes, and circulating or infiltrating inflammatory cells.

In summary, our study shows the involvement of the cAMP effector Epac-1 in the regulation of liver fibrosis. Fibrogenesis is associated with a reduced Epac-1 expression in vivo. Restoration of Epac-1 levels by PGE2 is associated with attenuated fibrogenic activity. In contrast, the COX inhibitor NFA attenuates hepatic Epac-1 expression, which is paralleled by an increased HSC activation and fibrogenesis. In HSC, but not in hepatocytes or KC, PGE2 restores Epac-1 expression levels and strongly affects Rho activity in these cells. Our studies reveal a pathway to modulate Epac-1 levels and thereby fibrogenesis, although our studies also show that
cell specificity is important when interfering with Epac-1 levels. Detailed insight into this pathway is essential to identify drug targets and understand the effects of COX inhibitors in chronic liver diseases.

Acknowledgments

CE3F4 was a gift of Dr. Frank Lezloalc’ (INSERM, UMR-1048, France Université de Toulouse, France). LX2 cells were kindly provided by S. L. Friedman (Mount Sinai Hospital, New York, NY).

Authorship Contributions

Participated in research design: Schippers, Beljaars, Lotersztajn, Schmidt, Poelstra.

Conducted experiments: Schippers, Post, Reker-Smit, Han, Munoz-Llancao.

Performed data analysis: Schippers, Beljaars, Poelstra.

Wrote or contributed to the writing of the manuscript: Schippers, Beljaars, Schmidt, Poelstra.

References


Address correspondence to: Dr. Klaas Poelstra, Department of Pharmacokinetics, Toxicology and Targeting, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands. E-mail: k.poelstra@rug.nl